I don't usually write about the starts of clinical trials, and I've even been known to send snarky replies to PR people who pitch them to me via email. I mean, really, tell me when the thing ends; that's the data investors care about, since it drives the stock price.
So I found it curious that CEL-SCI
Did CEL-SCI suddenly figure out a way to start and complete a clinical trial in one day? Was there something in the press release that gave investors additional confidence that Multikine would work? Not that I can see.
As best I can tell, this was just investors saying, "Finally!" The trial, which it's running with Teva Pharmaceutical
There's likely also a little excitement as investors look at CEL-SCI as the next Dendreon
The phase 3 trial looks well-planned, but I don't see much reason to jump in at this point. It's not clear that Multikine will work -- the phase 2 trial didn't have a control group -- and it's going to take a long time to get an answer. The endpoint is overall survival, which CEL-SCI believes will take three years in the standard of care group and hopefully longer in the Multikine group.
Investors looking for a company that's a little further along would be better off looking at Regeneron Pharmaceuticals